Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers

Abstract

A cannabis-based flavonoid pharmaceutical composition including any one or more selected from among the group of Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside and their derivatives selected from among the group of Geraldol, Rhamnetin, Isorhamnetin, Rhamnazin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and histone acetylases. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include but are not limited to brain, breast, colon, renal liver, lung, pancreatic, pigmented villonodular synovitis, prostate, leukemia, melanomam, tenosynovial giant cell tumor, as well as any other cancers that overexpress the oncogenic factors inhibited, by the cannabis flavonoids or their derivatives herein identified.

What is claimed is: 
     
         1 . A method of treating leukemia, comprising:
 administering to a patient in need thereof, a composition having a chemical structure as shown below, or any pharmaceutically acceptable salt thereof:   
       
         
           
           
               
               
           
         
         
           wherein:
 R1, R6, R7, and R10 are each hydrogen; 
 R2 is selected from a group consisting of hydroxide and a methoxy group; 
 R3 is each selected from a group consisting of hydrogen and a methoxy group; 
 R4 and R5 are each selected from a group consisting of hydrogen and hydroxide; 
 R8 and R9 are each selected from a group consisting of hydrogen, hydroxide, and a methoxy group; and 
 the bond between A and B is selected from a group consisting of a single flavanone bond and a double flavone bond. 
 
         
       
     
     
         2 . The method of  claim 1 , wherein the administration to the patient of the composition comprises administering the composition via a route selected from a group consisting of: a topical route, an oral route, and a rectal route. 
     
     
         3 . The method of  claim 1 , wherein the administration to the patient of the composition comprises injecting the composition into a location of the patient's body selected from the group consisting of: a vein, an epidural muscle, a subcutaneous location, an intrauterine location, and an intracerebroventricular location. 
     
     
         4 . The method of  claim 1 , wherein the administration to the patient of the composition comprises:
 selecting a dose of the composition based on at least one factor selected from a group consisting of the patient's condition, the patient's body weight, an extent of brain cancer, a form of the composition, a route of administration of the composition, and a duration of administration; and   providing the selected dose of the composition to the patient.   
     
     
         5 . The method of  claim 1 , wherein the administration to the patient of the composition comprises:
 selecting a dose of the composition; and   providing between 1 to 6 of the selected doses of the composition to the patient each day.   
     
     
         6 . The method of  claim 1 , wherein the administration to the patient of the composition comprises:
 selecting a dose of the composition within a range from 0.1 milligrams (mg) to 500 mg; and   providing the selected dose of the composition to the patient.   
     
     
         7 . The method of  claim 1 , wherein the leukemia comprises acute myeloid leukemia. 
     
     
         8 . The method of  claim 1 , wherein the composition comprises a carrier substance selected from a group consisting of: lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl benzoate, propyl benzoate, talc, magnesium stearate, and mineral oil. 
     
     
         9 . The method of  claim 1 , wherein the composition is formulated in at least one form selected from a group consisting of: a powder, a granule, a tablet, a capsule, a suspension, an emulsion, a syrup, an aerosol, a suppository, and an injectable solution. 
     
     
         10 . A method of treating leukemia, comprising:
 administering to a patient in need thereof, a composition having a chemical structure as shown below, or any pharmaceutically acceptable salt thereof:   
       
         
           
           
               
               
           
         
       
     
     
         11 . The method of  claim 11 , wherein the administration to the patient of the composition comprises administering the composition via a route selected from a group consisting of: a topical route, an oral route, and a rectal route. 
     
     
         12 . The method of  claim 11 , wherein the administration to the patient of the composition comprises injecting the composition into a location of the patient's body selected from the group consisting of: a vein, an epidural muscle, a subcutaneous location, an intrauterine location, and an intracerebroventricular location. 
     
     
         13 . The method of  claim 11 , wherein the administration to the patient of the composition comprises:
 selecting a dose of the composition based on at least one factor selected from a group consisting of the patient's condition, the patient's body weight, an extent of brain cancer, a form of the composition, a route of administration of the composition, and a duration of administration; and   providing the selected dose of the composition to the patient.   
     
     
         14 . The method of  claim 11 , wherein the administration to the patient of the composition comprises:
 selecting a dose of the composition; and   providing between 1 to 6 of the selected doses of the composition to the patient each day.   
     
     
         15 . The method of  claim 11 , wherein the administration to the patient of the composition comprises:
 selecting a dose of the composition within a range from 0.1 milligrams (mg) to 500 mg; and   providing the selected dose of the composition to the patient.   
     
     
         16 . The method of  claim 11 , wherein the brain cancer comprises acute myeloid leukemia. 
     
     
         17 . The method of  claim 11 , wherein the composition comprises a carrier substance selected from a group consisting of: lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl benzoate, propyl benzoate, talc, magnesium stearate, and mineral oil. 
     
     
         18 . The method of  claim 11 , wherein the composition is formulated in at least one form selected from a group consisting of: a powder, a granule, a tablet, a capsule, a suspension, an emulsion, a syrup, an aerosol, a suppository, and an injectable solution. 
     
     
         19 . A method of treating leukemia, comprising:
 administering to a patient in need thereof, a composition having a chemical structure as shown below, or any pharmaceutically acceptable salt thereof:   
       
         
           
           
               
               
           
         
       
     
     
         20 . A method of treating leukemia, comprising:
 administering to a patient in need thereof, a composition having a chemical structure as shown below, or any pharmaceutically acceptable salt thereof: